Statistical design of Path to Prevention platform trial in early neuronal alpha-synuclein disease
The Path to Prevention (P2P) platform trial is a first-in-class, phase 2A, randomized, double-blind, placebo-controlled learning study. Its design expedites the assessment of investigational therapies…